Synthesis and structural elucidation of biliary excreted thioether derivatives of mitoxantrone

References

• Bax A., Griffey R. H., Hawkins B. L. Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR. Journal of Magnetic Resonance 1983; 55: 301
   Web of Science ®Google Scholar
• Betowski L. D., Korfmacher W. A., Lay D. W., Potter D. W., Hinson J. A. Direct analysis of rat bile for acetaminophen and two of its conjugated metabolites via thermospray liquid chromatography/mass spectrometry. Biomedical and Environmental Mass Spectrometry 1987; 14: 705–709
   PubMedGoogle Scholar
• Blanz J., Zeller K.-P. 13C-Markierung der Seitenketten von Mitoxantrone. Journal of Labelled Compounds and Radiopharmaceutical 1989; 27: 91–101
   Google Scholar
• Blanz J., Mewes K., Beth M., Ehninger G., Zeller K.-P. Carbon-13 NMR studies of some di- and tetra-substituted anthracene-9,10-dione derivatives related to the anticancer drug mitoxantrone. Magnetic Resonance in Chemistry 1991a; 29: 1072–1074
   Google Scholar
• Blanz J., Mewes K., Ehninger G., Proksch B., Greger B., Waidelich D., Zeller K.-P. Isolation and structure elucidation of urinary metabolites of mitoxantrone. Cancer Research 1991b; 51: 3427–3433
   PubMed Web of Science ®Google Scholar
• Blanz J., Mewes K., Ehninger G., Proksch B., Waidelich D., Greger B., Zeller K.-P. Evidence for oxidative activation of mitoxantrone in human, pig, and rat. Drug Metabolism and Disposition 1991c; 19: 871–880
   PubMed Web of Science ®Google Scholar
• Chiccarelli F. S., Morrison J. A., Cosulich D. B., Perkinson N. A., Ridge D. N., Sum F. W., Murdock K. C., Woodward D. L., Arnold E. T. Identification of human urinary mitoxantrone metabolites. Cancer Research 1986; 46: 4858–4861
   PubMed Web of Science ®Google Scholar
• Duthie S. J., Grant M. H. The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. British Journal of Cancer 1989; 60: 566–571
   PubMed Web of Science ®Google Scholar
• Ehninger G., Proksch B., Heinzel G., Schiller E., Weible K. H., Woodward D. L. The pharmacokinetics and metabolism of mitoxantrone in man. Investigational New Drugs 1985a; 3: 109–116
   Google Scholar
• Ehninger G., Proksch B., Schiller E. Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography. Journal of Chromatography 1985b; 342: 119–127
   PubMed Web of Science ®Google Scholar
• Ehninger G., Schuler U., Proksch B., Zeller K.-P., Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clinical Pharmacokinetics 1990; 18: 365–380
   PubMed Web of Science ®Google Scholar
• Faulds D., Balfour J. A., Chrisp P., Langtry H. D. Mitoxantrone. A review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 41: 400–449
   PubMed Web of Science ®Google Scholar
• Haroldson P. E., Reilly M. H., Hughes H., Gaskell S. J., Porter C. J. Characterisation of glutathione conjugates by fast atom bombardment/tandem mass spectrometry. Biomedical Mass Spectrometry 1988; 15: 615–621
   Google Scholar
• Kolodziejczyk P., Reszka K., Lown J. W. Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone. Free Radicals in Biology and Medicine 1988; 5: 13–25
   PubMed Web of Science ®Google Scholar
• Llesuy S. F., Arnaiz S. L. Hepatotoxicity of mitoxantrone and doxorubicin. Toxicology 1990; 63: 187–198
   PubMed Web of Science ®Google Scholar
• Mewes K., Blanz J., Ehninger G., Gebhardt R., Zeller K.-P. Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Research 1993; 53: 5135–5142
   PubMed Web of Science ®Google Scholar
• Murdock K. C., Child R. G., Fabio P. F., Angier R. B., Wallace R. E., Durr F. E., Citarella R. V. 1,4-Bis-[(aminoalkyl)amino]-9,10-anthracenediones. Journal of Medicinal Chemistry 1979; 22: 1024–1030
   PubMed Web of Science ®Google Scholar
• Murdock K. C., Durr F. E. American Cyanamid Company. US Patent. 4197249, 1980
   Google Scholar
• Nguyen B., Gutierrez P. L. Mechanism(s) for the metabolism of mitoxantrone: electron spin resonance and electrochemical studies. Chemico-Biological Interactions 1990; 74: 139–162
   Google Scholar
• Pearson P. G., Threadgill M. D., Howard W. N., Baille T. A. Application of tandem mass spectrometry to the characterization of derivatized glutathione conjugates. Studies with S-(N-methylcarbamoyl)-glutathione, a metabolite of the antineoplastic agent N-methylformamide. Biomedical and Environmental Mass Spectrometry 1988; 16: 51–56
   Google Scholar
• Reszka K., Hartley J. A., Kolodziejczyk P., Lown J. W. Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of 14C-labeled drug. Biochemical Pharmacology 1989; 38: 4253–4260
   Google Scholar
• Reszka K., Kolodziejczyk P., Lown J. W. Horseradish peroxidase-catalyzed oxidation of mitoxantrone: spectrophotometric and electron paramagnetic resonance studies. Journal of Free Radicals in Biology and Medicine 1986; 2: 25–32
   PubMedGoogle Scholar
• Richard B., Fabre G., Fabre I., Cano J. P. Excretion and metabolism of mitoxantrone in rabbits. Cancer Research 1989; 49: 833–837
   Google Scholar
• Wolf C. R., MacPherson J. S., Smyth J. F. Evidence for the metabolism of mitoxantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases. Biochemical Pharmacology 1986; 35: 1577–1581
   PubMed Web of Science ®Google Scholar
• Zee-Cheng R. K. Y., Cheng C. C. Anthraquinone anticancer agents. Drugs of the Future 1983; 8: 229–249
   Google Scholar